Compare ConocoPhillips (COP) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Eli Lilly And Co — how do they compare? ConocoPhillips trades at $134.7 (market cap $161.21B), while Eli Lilly And Co trades at $1,173.73 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 6.5× ConocoPhillips's market cap, and ConocoPhillips pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Eli Lilly And Co for 93 Days on average.
| COP | LLY | |
|---|---|---|
Market Cap | $161.21B | $1.04T |
Volume | 6,058,403 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $141.22 | $1.28K |
52-Week Low | $85.66 | $799.57 |
Typical Hold Time | 79 Days | 93 Days |
Enterprise Value | $176.81B | $1.09T |
Dividend Yield | 2.5% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.52, up 3.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global. Valuation metrics appear reasonable with P/E at 17.75 and EV/EBITDA at 6.36, while profitability remains solid with 14.65% net income margin and 14.14% ROE.
Outlook remains positive with consensus price target of $154.75 representing 15% upside potential. Key risks include oil price volatility and geopolitical exposure in international operations. The company's strong cash flow generation and strategic LNG expansion provide growth catalysts, though investors should monitor execution on asset sales and energy market dynamics.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
